免疫检查点阻断增强[177Lu]Lu-DOTA-JR11 PRRT在SSTR2异质性双侧肿瘤模型中的远隔效应
该研究在SSTR2异质性双侧鼠黑色素瘤模型中,评估[177Lu]Lu-DOTA-JR11 PRRT联合抗PD-L1单抗能否增强远隔效应。结果显示联合治疗显著抑制双侧肿瘤生长、延长生存并降低[18F]FDG摄取,伴随CD8+细胞浸润和M1巨噬细胞增加及MDSCs和M2巨噬细胞减少。
要点
- PRRT单药选择性抑制SSTR2阳性肿瘤,对SSTR2阴性肿瘤疗效甚微
- PRRT联合抗PD-L1显著抑制双侧肿瘤生长并延长生存
- 联合治疗增强系统性免疫激活并改善肿瘤免疫微环境
核心结论
- PRRT联合PD-L1阻断可重塑肿瘤免疫微环境,激发系统性抗肿瘤免疫,在SSTR2异质性肿瘤中增强远隔效应。
研究设计与样本
- 研究建立双侧SSTR2异质性鼠黑色素瘤模型,对侧植入B16F10-SSTR2与B16F10野生型肿瘤。
- 小鼠接受生理盐水、PRRT、抗PD-L1单抗或联合治疗,评估肿瘤生长、生存、PET/CT、组织病理、免疫谱及血清细胞因子。
主要发现
- PRRT单药选择性抑制SSTR2阳性肿瘤,对SSTR2阴性肿瘤疗效甚微。
- 联合治疗显著抑制双侧肿瘤生长、延长生存并降低肿瘤[18F]FDG摄取。
- 联合治疗伴随颗粒酶B表达增加、CD8+细胞浸润增强、M1巨噬细胞和效应记忆T细胞扩增,以及MDSCs和M2巨噬细胞减少。
- 联合治疗组血清IFN-γ和IL-2水平显著升高,提示强烈的系统性免疫激活。
临床怎么用
- 该策略可能有助于解决核素治疗中靶点表达异质性的问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The overexpression of somatostatin receptor (SSTR) in neuroendocrine neoplasms (NENs) provides a molecular basis for treatment with peptide receptor radionuclide therapy (PRRT). However, heterogeneous SSTR expression limits therapeutic efficacy. Immune checkpoint inhibitors (ICIs) enhance the abscopal effect of external radiotherapy. This study investigated whether combining PRRT using the SSTR antagonist [177Lu]Lu-DOTA-JR11 with anti-PD-L1 monoclonal antibody (mAb) therapy could enhance the abscopal effect in an SSTR2-heterogeneous bilateral tumor model. METHODS: A bilateral SSTR2-heterogeneous murine melanoma model was established by contralateral implantation of B16F10-SSTR2 and B16F10-wildtype tumors. Mice received saline, PRRT, anti-PD-L1 mAb, or combination therapy. Tumor growth, survival, PET/CT imaging, histopathology, immune profiling (including PD-L1 expression, CD45+ cells, CD8+ cells, myeloid-derived suppressor cells [MDSCs], and macrophage phenotypes), and serum cytokine levels were assessed to evaluate local and systemic antitumor responses. RESULTS: PRRT monotherapy selectively inhibited SSTR2-positive tumors but showed minimal efficacy against SSTR2-negative tumors. Combination therapy significantly suppressed the growth of both tumors, prolonged survival, and reduced [18F]FDG uptake in tumors. These effects were accompanied by increased Granzyme B expression, enhanced CD8+ cell infiltration, expansion of M1 macrophages and effector memory T cells, and reductions in MDSCs and M2 macrophages. Serum IFN-γ and IL-2 levels were significantly elevated, indicating robust systemic immune activation. CONCLUSION: PRRT combined with PD-L1 blockade remodels the tumor immune microenvironment, elicits potent systemic antitumor immunity, and enhances the abscopal effect in SSTR2-heterogeneous tumors. This strategy may help address target-expression heterogeneity in radionuclide therapy.
引用
- Cheng Z, Zhou H, Liu L, et al. Immune Checkpoint Blockade Enhances the Abscopal Effect of [177Lu]Lu-DOTA-JR11 PRRT in an SSTR2-Heterogeneous Bilateral Tumor Model. Eur J Nucl Med Mol Imaging. 2026. PMID: 42185645. doi:10.1007/s00259-026-07940-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。